/
PYXS
$2.86+$0.09 (+3.25%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$175.5M
63M shares
52-week range
$0.97 – $5.55
41% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-10.34
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $16.1M | $13.9M |
| Cost of revenue | $0 | $444.0K | $0 | $0 | $0 | $475.0K | $2.4M |
| Gross profit | $0 | −$444.0K | $0 | $0 | $0 | $15.7M | $11.5M |
| Gross margin | — | — | — | — | — | 97.1% | 82.8% |
| R&D | $1.2M | $8.6M | $51.1M | $86.1M | $49.6M | $58.7M | $73.7M |
| Operating income | −$2.9M | −$12.9M | −$69.7M | −$123.5M | −$82.2M | −$89.5M | −$84.4M |
| EBITDA | −$2.8M | −$12.4M | −$75.3M | −$120.0M | −$71.9M | −$65.5M | −$73.7M |
| Net income | −$2.8M | −$12.8M | −$76.0M | −$120.7M | −$73.8M | −$77.3M | −$79.6M |
| Net margin | — | — | — | — | — | -478.9% | -574.5% |
| EPS (diluted) | -0.08 | -0.37 | -2.53 | -3.57 | -1.85 | -1.32 | -1.28 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $50000 | $-1.24 | $-1.46–$-1.00 | 6 |
| 2027 | $4M | $-1.26 | $-1.66–$-0.83 | 6 |
| 2028 | $16M | $-1.26 | $-1.95–$-0.41 | 6 |
| 2029 | $43M | $-1.01 | $-1.01–$-1.01 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.71
Price
$2.86
Implied downside
-40%
Peer comparison
Pyxis Oncology, Inc. Common Stock
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
www.pyxisoncology.com- Employees
- 56
- IPO / List date
- Oct 8, 2021
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds PYXS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 888,680 | $1.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PYXS yet.
